Organisation paid for research Program year 2022 Source: CMS Open Payments

Avail Research

Neither a doctor nor a teaching hospital

Research payments

$121,693

7 payments

Through program year 2022, Avail Research is reported as receiving $121,693 in research payments, across 7 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$2,500	1
2021	Research	$5,031	2
2020	Research	$28,845	2
2019	Research	$85,317	2

Breakdown

Who paid Research payments · program years 2019–2022

Horizon Therapeutics plc $121,693 7 payments

Studies the money was for Research payments · program years 2019–2022

A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa Pegloticase Mirror Ol $75,573 1 payment
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror [Ol]) $26,345 2 payments
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa Pegloticase Mirror Randomized Controlled Trial RCT $9,744 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $5,000 1 payment
A Randomized Double-Blind Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Randomized Controlled Trial RCT ) $3,000 1 payment
A Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Ol ) $2,031 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.